Searchable abstracts of presentations at key conferences in endocrinology

ea0090p261 | Late-Breaking | ECE2023

Factored aldosterone can help distinguish mineralocorticoid resistance from aldosterone deficit hypoaldosteronism

Gabriel Ruiz Sanchez Jorge , Calle Alfonso , Angel Rubio Herrera Miguel , Paz de Miguel Novoa Maria , Gomez Hoyos Emilia , Runkle Isabel

Introduction: Hypoaldosteronism can be induced by a deficit of aldosterone production (AldDef) or a mineralocorticoid resistance (MinRes). Experts have proposed to use hyperkalemia-based aldosterone values for this purpose. However, there is no a range of aldosterone values indicating one of this type of hypoaldosteronism. In 2008, Adam W. R.1 hypothesized that the factored aldosterone (FAldo) could be useful differentiating hypoaldosteronism secondary to MinRes fro...

ea0081p215 | Thyroid | ECE2022

Is there a familial predisposition to severe amiodarone-induced thyrotoxicosis? Report of two cases

Bernaldo Madrid Blanca , Mera Carreiro Sara , Perez Candel Xavier , Lopez Nevado Celia , Espinosa De Los Monteros Patricia , Hernandez Olmeda Fernando , Ochagavia Camara Santiago , Runkle Isabel , Gabriel Ruiz Sanchez Jorge , Pazos Guerra Mario

Introduction: Amiodarone-induced thyrotoxicosis (AIT) occurs in up to 6% of patients taking this medication in iodine sufficient areas and in up to 10% of patients in iodine deficient areas and has a high rate of mortality, that can reach 50% in untreated severe forms. There are two main types (1 and 2) described, although usually we find mixed types, with both components. Below, we describe the cases of two brothers that developed severe mixed forms of amiodarone-induced thyr...

ea0090p336 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Oral Semaglutide Improves Metabolic Outcomes in Type 2 Diabetes: A Spain-based Study

Casado Carlos , Jair Cardenas Salas Jersy , Miguel Sierra Poyatos Roberto , Montoya Alvarez Teresa , Meneses Gonzalez Diego , Gabriel Ruiz Sanchez Jorge , Luiza Luca Bogdana , Sanchez Lechuga Begona , de los Angeles Velez Romero Maria , Vazquez Martinez Clotilde

Objectives: To evaluate the changes in HbA1c, basal glucose, weight, and lipid profile in patients with type 2 diabetes after starting oral semaglutide.Methods: This study was conducted in Madrid, Fundación Jiménez Díaz, Infanta Elena and General de Villalba hospitals. A total of 75 patients with type 2 diabetes were included. The mean age was 62.0±10.5 years and 60% were men. The mean duration of diabetes was 7.3±6.6 years, and 66.7...

ea0070ep197 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain

Cardenas Jersy , Sanchez Gomez Nancy , Miguel Sierra Poyatos Roberto , Luiza Luca Bogdana , Modroño Mostoles Naiara , Montoya Alvarez Teresa , Silva Rodriguez Maria Jesus , Ortega Juaristi Maite , Meneses González Diego , De Los Angeles Gonzalo Redondo Maria , Galdon Sanz–Pastor Alba , Ruiz Sanchez Jorge , De La Paz Gómez Montes María , Cruces Vega Cristina , Vazquez Martinez Clotilde

Objectives: Semaglutide was approved for the treatment of T2DM patients with a body mass index (BMI) > 30kg/m2 by the Spanish National Health Service in May 2019. We evaluate clinical outcomes of patients on previous treatment with any another GLP1–RA that switch to Semaglutide.Material and Methods: Retrospective analysis. Sixty–five T2DM patients were included. Demographic data, anthropometric, systolic blood pressure (SBP), d...